Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Below is a positive story about Leronlimab and reveals a potential benefit in regards to antibodies.
“We don’t know for sure if the Leronlimab was what turned her around. I believe it probably did, the improvement she had after she got the drug was dramatic,” Dr. Yang said.
The drug is now being studied in a placebo-controlled clinical trial and UCLA is one of the trial sites.
Dr. Yang said not all of his patients responded to Leronlimab as well as Mottet and the trial results will offer more insight into its efficacy. But when he last read her antibody count, it was over 100,000.
“She’s about 10 times higher than the typical person’s antibodies,” Dr. Yang said.
Dr. Yang recently published a study on antibodies in COVID-19 patients in the New England Journal of Medicine, and found that antibodies fall sharply in the first three months after battling the virus, especially in mild cases of COVID-19. But Mottet was a rare exception.
spectrumnews1.com/...
Many have asked why no partner for CytoDyn? We do have a partner in Samsung Biologics. They agreed to manufacture Leronlimab. And, here is another juicy tidbit:
“Thanks to a health care system that ranks second to none, mass testing, and a vast surveillance system that made precise contact tracing possible, as of May 12 South Korea had only 258 coronavirus deaths in a country of more than 51 million people. Even though the country never went on a full lockdown, two weeks ago it reported no new domestic cases thanks to a combination of these measures and voluntary social distancing. To be sure, this victory would not have been possible without Samsung.”
“Also last month, a U.S. biotech firm reported promising results in treating coronavirus patients with its HIV drug leronlimab, which Samsung Biologics will supply for up to $1 billion over the next few years.”
Which country boasts the most deaths? Uncle Sam and Uncle Trump! What has Big Pharma with all their billions and billions and billions of brainpower and resources?
https://foreignpolicy.com/2020/05/13/south-korea-pandemic-democracy-chaebol-samsung-corporate-reform/
Latest numbers are 1,040,233 Covid-19 cases with 58,819 deaths. Below article stats a 3rd of cases require hospitalization. Working with that figure of 346,397, 17% who require hospitalization will die. Recent Gilead study states 37 died from 397 patients or 9.3%. If all cases are serious, then 32,215 would die using remdesivir. I believe we need more information to determine the effectiveness of remdesivir.
https://www.businessinsider.com/coronavirus-us-hospitalizations-per-capita-by-age-state-race-2020-4
FF to 31.15 for Dr. Otto Yang heading trials at UCLA discussing Leronlimab.
You can watch the replay. Not the best quality but sounds like from comments all very good news. I am watching replay now.
https://register.gotowebinar.com/recording/recordingView?webinarKey=6072304059315473677®istrantEmail=michael.goldbarth%40gmail.com
Thanks, we can only hope. Lots of things yet to happen. CYDY posted a position on Linkedin for Supply Chain Project Management a few weeks ago. My fear is timing here. Eventually, this virus will start to die out. I fear we got a little too late into the game and by the time approval comes, it may not matter much.
https://www.linkedin.com/jobs/search?locationId=OTHERS.worldwide&%3Bf_C=15642566&trk=top-card_top-card-primary-button-top-card-primary-cta&redirect=false&position=1&pageNum=0
In this interview on Cheddar, Dr. Nader Pourhassan advised that Leronlimab will be free to the 1st 10,000 patients and that CytoDyn would be paid via a government grant-Assuming Leronlimab gets approved to treat COVID-19. Perhaps CYDY can price Leronlimab 50% of treating HIV per injection works out to $451 per treatment. Anybody care to guesstimate what we may be looking at here? When I hear ‘grant,’ my excitement wains. I realize we are in a pandemic; however, should Leronlimab be approved, CYDY is in no financial position to give this product away for free or to lose money.
At the very least, I would expect enough funds to ensure CytoDyn completes HIV FDA submission along with cancer and other indications. If Leronlimab emerges as the most used treatment, this would obviously potentially save many lives and allow for a quicker return to normal, which would be a huge boost to the world’s economy.
From what I have researched on the web, there is no consensus knock it out of the ballpark treatment being used on a wide scale. If there was, why are we approaching 100,000 deaths? If Chloroquine phosphate works, then no one should be dying. Yesterday’s news touted an MD combining this drug with zinc. I assume the CYDY team will keep us up-to-date, we usual, and we will know a lot more in the coming weeks.
https://cheddar.com/media/cytodyn-ceo-on-fast-tracking-companys-hiv-drug-to-help-coronavirus-patients-in-critical-condition
More good news from Leronlimab treatment against COVID-19. They plan to initiate a trial for 342 patients double-blinded-Meaning neither party will know who is getting the placebo. How will they prevent those who get the placebo from potentially dying; even though, they plan to give them the real treatment afterwards?
https://www.cytodyn.com/newsroom/press-releases/detail/405/treatment-with-cytodyns-leronlimab-indicates-significant
He lost a lot more than his shirt; He lost his SHIT!
Well, at least it is something. I do sense that a lot of Big Pharma is branding. I don’t give a shit about branding. All I care about is something that works. If Leronlimab proves to be successful in the next batch of patients (assume 50 give or take), then people will have to stand up and take notice. It probably took a lot just to get an MD to test out Leronlimab. Well done.
Dr. Bruce Patterson discussing testing for the virus. His involvement with CYDY has boosted my confidence in Leronlimab.
https://news.yahoo.com/coronavirus-testing-vital-not-perfect-003237966.html
CYDY opens at $1.19!
LOL! I luv it when Nader says: 'Thank you for having me!'
All the shorts, just like all the critics of Vincent van Gogh, will be forgotten. This will be a little bit different, as we will live to see Leronlimab benefit humanity for the next few decades and we will be the beneficiaries knowing we helped fund it. I feel like things are starting to speed up, and very soon, Leronlimab will inject the world with life. Question: Should Leronlimab be approved to treat the coronavirus, will Donald Trump pronounce it correctly? I want to see Donald Trump and Nader Pourhassan on Proactive Investors!
Nice Sunday Surprise! These guys do not take a day off! It would be interesting to know if the patients on trials for HIV experienced less cold and flu while on PRO140/Leronlimab? This may substantiate benefit for coronavirus.
This is great news. Obviously, the small team at CYDY has been hard at work. I know it is easy to criticize delays, etc. but look what they are doing with such a small group. Kudos to them all. I am a long-term investor. I buy and hold. No B.S. selling when the market goes down and then buying back in.
They’ve done great work expanding their horizons beyond the U.S. into Asia. Soon enough this will bear fruit. Who cares where the partnership comes from? If Leronlimab works, a patient isn’t going to give a rat’s ass who our partners are. When you’re sick, you don’t care about Big Pharma branding. All you care about is getting your health back. Go CYDY Go!
Leronlimab in the news for Coronavirus. * I thought we were in phase II?
“CytoDyn is studying leronlimab (PRO 140), a CCR5 antagonist, as a possible treatment. It is being studied in Phase II clinical trials for HIV and the U.S. Food and Drug Administration (FDA) has granted it Fast Track status.”
https://www.biospace.com/article/coronavirus-update-disconnect-between-trump-administration-and-public-health-experts-and-biopharma-efforts-to-develop-and-test-drugs-and-vaccines/
Sorry meant to write 'cancer trials.'
I can’t blame him. He did what was necessary to move forward. The market does not care. Money is money. If monotherapy also gets approved, CYDY will dominate the HIV market. I assume no other pharma in the HIV space wanted to promote Leronlimab and this hurt their own sales. If these trials prove to be anywhere as successful as the 1st few patients, Big Pharma will call-Likely based in Europe and then it will be all over.
Another great interview by Evan Gappelberg. He had me convinced so much I wanted to go out and buy a company to use AR! I hope they can get Harry Rosen to sign up. I think they would be a great fit.
Excellent interview! Once he announces BLA submission, it will be onwards and upwards. We will not look back.
So much for the Hindenburg report! Kudos to Evan Gappelberg for a brilliant retort. He absolutely destroyed that report and even named the perpetrator. I’m sorry he had to waste his holiday weekend dealing with this crap. I bought back in last week and again this morning. I apologize for getting duped by this shorter.
Yes, found this gem! This is not vapour. The technology works and once more and more companies come on board and start applying to more of their products, the shorts will get caught with their pants down!
https://vimeo.com/351640973
Essentially, this shorter is saying any company that uses an on-line service to update shareholders or potential shareholders or to promote their company is a scam. So, no one should purchase shares of any company that shows transparency or openly communicates to shareholders. Who will they attack next? Perhaps companies that broadcast their quarterly meetings or issue many press releases?
This is a great example of the technology.
https://www.thewrightbrothersusa.com/collections/the-wilbur-and-orville-collection/products/1360-series-23k-gold-sunglasses
I bought back in the other day. I only sold because Gold Romios CFO told me never heard of NexTech. He was wrong. This is 2nd law firm. I assume this has no merit? I do not understand why they are doing this?
I am 99% certain Leronlimab will be approved for HIV. I hope it will have a future for cancer. I suspect it will be used as combo treatment for cancer. Anything to reduce the use of surgery, chemo and radiation would be a Godsend.
Below is a paper about PRO140 for HIV from 2008. This should dispel all the B.S. about Leronlimab being a hoax. I feel sorry for Dr. Nader Pourhassan having to promote Leronlimab door to door like a traveling salesman but I gather he needs to do what is necessary to keep this treatment alive. I sense Big Pharma would like him to go away. They want to bury this. It will have a huge impact for HIV. I hope they find the funds to do a proper large study for cancer.
“Conclusions. This trial established clear proof of concept for PRO 140 as a potent antiretroviral agent with extended activity after a single dose.”
https://academic.oup.com/jid/article/198/9/1345/834086
Everyone is focusing on Coronavirus. It should also be noted the press release states the 2 companies will explore working on cancer. I suspect this may be a way for CYDY to avoid further dilution to pay for a much larger trial. Smart move by Nader Pourhassan preserving shareholder value.
This is obviously a desperate situation for China. How long will it take to find a few patients to test Leronlimab on? It’s safe, what have they got to lose? NP is doing what he can to prove Leronlimab works.
Once the BLA is submitted and hopefully approved, some on here will be singing a different tune. I would venture to guess; this investment has a much higher payout potential than many others based solely on return.
“CytoDyn and Longen will begin exploring opportunities for leronlimab for the treatment of the 2019 Novel Coronavirus (2019-nCoV) and cancer.”
Thanks for this. I bought back in confidence restored. I cannot believe that CFO. He picked up the phone. I guess he is a glorified receptionist. I transferred money for my TFSA contribution and will invest more when it lands.
Yes, I believe we are getting close. I'm 99% sure Nurown will be approved to treat ALS. No cure but a very meaningful treatment to extend the quality of life for many. I hope they can expedite this.
I have no idea when the bottom will be reached and I am afraid. I called Romios Gold, same voice in recording and spoke to CFO. Has not heard of NexTech AR. If NexTech addresses that, maybe I will be back in. They do have something here but it needs to be developed. Question is at what cost?
I love Evan Gappelberg as a salesman. He comes across very professional and down to earth. I wish one of my other positions (CYDY) had a similar CEO. I’m sure CYDY would be trading much higher with a better presenter. I also own BCLI with similar CEO issues. I look at a lot more than the face of the company. I look at the product or in the case of biotech, the science. I sense NexTech needs a bigger team and thus an infusion of cash to accelerate their technology. For the next little while, I will be watching from the stands.
Good question? Maybe because they posted taped recorded conversations and in order to sue someone you need to be able to get compensated. All they could hope to get is an apology or retraction. Not very professional taping someone without letting them know.
Starwood Research could use some NexTech. The presentation was high school to put it mildly. I am happy the whole NexTech team responded but I am a little concerned they did not respond to some of the very specific clients the report mentioned. By the way, the report by the shorter looked very high school as well. My gut tells me to stay away. I am disappointed, in that even though I only had a small position compared to my portfolio, I have invested more time following this company than some of my others.
$1.38 Canadian. Sorry posted bad link below.
Stock is getting hammered at the opening bell.
https://finance.yahoo.com/quote/NEXCF?ltr=1
I do take offense with the report criticizing CEO for promoting company. I believe this is the future and I believe AR will be the future. In my free time, I write plays. Good writing is rewriting. When I look back at a 1st draft compared to something I’ve worked on for months, sometimes I can barely recognize it. I feel like NexTech is in 1st or 2nd draft mode. One day, they will get there but will they get there fast enough or will they just pave the way for someone else?
When I bought in part of me was hoping they would be bought by someone much bigger. I’m going to watch for the next little while. I can always buy back in. It’s a good story but I’m not sure if it will be a fairy tale happy ending. I hope I am wrong because I feel the same energy and spirit, I felt early in my career when I landed with a similar Startup company decades ago.
I only had $3,500 worth of shares spread across my open account, TFSA and RRSP. I sold everything after my call to the CFO, who picked up the phone at Romios Gold. I admit I got spooked by the report, took a small profit and ran to the sidelines. I am concerned they did not directly address some of the calls made to their clients. How can a company not know they are doing business with NexTech and we had others who have not implemented AR or were less than impressed?
The reason I 1st invested was in hopes a big company like New Balance or Harry Rosen would become a client. It makes so much sense. To be able to move product around and kind of see it on yourself. I sense there is a lot of work behind the scenes to make the AR magic happen. It certainly is not vapour, as the report claims. The problem here is the value. There are other ways to display product. As much as I like what they are doing, I’m not 100% sure it will be worth it. See below from Harry Rosen.
https://www.harryrosen.com/en/footwear/boots/barker-premium/chatsworth-fur-lined-boots/p/20055298
Harry Rosen did a really cool hologram with ARHT Media. * I feel, yes, we have something here but I’m getting the same angst Kevin O’Leary would get on the Dragon’s Den. Come back to me with more numbers and I want to see detailed numbers. I don’t want to hear; we’re planning to use the service but not sure when or how.
https://ca.proactiveinvestors.com/companies/news/104532/arht-media-partners-with-harry-rosen-to-bring-its-first-humagram-to-canadian-stores-58600.html
* At the end of the presentation, the audio was really bad. It was very unprofessional.